Oncor Inc. announced Wednesday that it has received approvalfrom FDA to market its DNA-based assay for detecting andmonitoring leukemia and lymphoma in bone marrow.

Bone marrow testing is a new indication for the Gaithersburg,Md., company's (NASDAQ:ONCR) already-approved B/T BlueGene Rearrangement Test System. "This new indication shouldenable physicians to diagnose and track these conditions (suchas leukemia and lymphoma) sooner and more effectively sincethese cancers will generally manifest themselves in the bonemarrow before expanding into the peripheral blood," saidGeorge Evanega, Oncor's president and chief operating officer.

Oncor's B/T Blue Test System, for use in the early detection andmanagement of cancer and other genetic diseases, is currentlyused in more than 100 U.S. labs, the company said.

(c) 1997 American Health Consultants. All rights reserved.